Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword

JAMA Oncol. 2018 Aug 1;4(8):1116-1117. doi: 10.1001/jamaoncol.2017.4606.

Authors

Chad Tang¹, Wen Jiang¹, Timothy A Yap^{2

3}

Affiliations

¹ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
² Department of Investigational Cancer Therapeutics (Phase I Program), Department of Thoracic/Head and Neck Medical Oncology, Institute for Applied Cancer Science.
³ Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston.

PMID: 29327039
DOI: 10.1001/jamaoncol.2017.4606

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
ErbB Receptors
Humans
Immunotherapy
Lung Diseases, Interstitial*
Lung Neoplasms*
Nivolumab

Substances

Nivolumab
EGFR protein, human
ErbB Receptors